Axsome Therapeutics Inc (NASDAQ:AXSM) – Research analysts at Cantor Fitzgerald lifted their FY2017 EPS estimates for shares of Axsome Therapeutics in a report issued on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst C. Russo now forecasts that the company will earn ($1.65) per share for the year, up from their prior estimate of ($1.79). Cantor Fitzgerald has a “Buy” rating and a $13.00 price target on the stock.
A number of other research firms also recently weighed in on AXSM. Aegis restated a “buy” rating on shares of Axsome Therapeutics in a report on Tuesday, March 21st. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 24th.
Shares of Axsome Therapeutics (NASDAQ:AXSM) traded down 2.53% during midday trading on Thursday, hitting $3.85. The company had a trading volume of 148,003 shares. The firm’s market capitalization is $73.90 million. Axsome Therapeutics has a 1-year low of $3.53 and a 1-year high of $12.69. The stock has a 50 day moving average price of $4.20 and a 200 day moving average price of $5.71.
Large investors have recently made changes to their positions in the company. Baldwin Brothers Inc. MA acquired a new stake in shares of Axsome Therapeutics during the third quarter valued at $119,000. State Street Corp boosted its stake in shares of Axsome Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 134,688 shares of the company’s stock valued at $908,000 after buying an additional 8,466 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Axsome Therapeutics by 0.7% in the third quarter. JPMorgan Chase & Co. now owns 1,592,856 shares of the company’s stock valued at $12,552,000 after buying an additional 10,625 shares during the last quarter. 33.07% of the stock is owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.